55 completed, 7 terminated, 6 recruiting, 5 unknown. 20 Phase 2, 20 Phase 4, 13 Phase 3, 10 Not applicable, 8 Phase 1.
Follow Guanfacine: new trials by email Literature Review of Guanfacine trials Research Report on Guanfacine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Guanfacine and Cromolyn Sodium for POTS: The DBPOTS Trial Guanfacine (GFC), Cromolyn Sodium, Placebo - Postural Orthostatic Tachycardia Syndrome (POTS), Dysautonomia | Early Phase 1 | Not yet recruiting | Johns Hopkins University | 25 | 2026-11-15 | 2026-10-09 |
| ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression Guanfacine, Sertraline - Depression | Phase 2 | Recruiting | Stanford University | 162 | 2026-03-03 | 2026-03-05 |
| Treating Young Children With Attention Deficit Hyperactivity Disorder Guanfacine (GUA), Methylphenidate (MPH) - Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 4 | Recruiting | Children's Hospital Medical Center, Cincinnati | 370 | 2026-02-16 | 2026-09-14 |
| Guanfacine for Alcohol Use Disorder (AUD) Guanfacine Extended Release (XR), Placebo - Alcohol Use Disorder | Phase 2 | Recruiting | Indiana University | 200 | 2025-10-03 | 2026-05-11 |
| Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS) Guanfacine Hydrochloride Immediate Release, Placebo - Hyperactivity in Children With Down Syndrome, Impulsivity in Children With Down Syndrome | Phase 2 | Terminated | Rachel G. Greenberg, MD, MB, MHS | 3 | 2024-12-09 | 2026-04-17 |
| Guanfacine Extended-release for Adolescents With Cannabis Use Guanfacine Extended Release Oral Tablet, Residential withdrawal, Engagement with alcohol and other drug services - Cannabis Use Disorder | Phase 2 | Recruiting | Orygen | 100 | 2023-07-27 | 2025-07-31 |
| The BIomarker Guided (BIG) Study for Depression Guanfacine Tablets - Major Depressive Disorder | Phase 4 | Completed | Stanford University | 28 | 2022-09-14 | 2025-03-20 |
| Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study Guanfacine, Placebo - Critical Illness, Delirium | Phase 2 | Completed | Vanderbilt University Medical Center | 46 | 2021-05-04 | 2026-02-19 |
| Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome Guanfacine Extended Release, Placebo - Prader-Willi Syndrome, Aggression | Phase 4 | Completed | Maimonides Medical Center | 15 | 2020-12-17 | 2024-08-19 |
| The Effect of Guanfacine on Delirium in Critically Ill Patients Guanfacine, Placebo - Delirium | Phase 3 | Completed | University of Alabama at Birmingham | 100 | 2020-11-23 | 2025-04-15 |
| Combining Varenicline and Guanfacine for Smoking Cessation Varenicline, Guanfacine ER - Smoking Cessation | Phase 2 | Completed | Yale University | 167 | 2020-11-01 | 2026-06-09 |
| Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use Disorders Guanfacine ER, Placebo - Alcohol Use | Phase 2 | Recruiting | Yale University | 160 | 2020-08-10 | 2026-02-27 |
| Affective Dysregulation (AD) in Children With ADHD Treated by Guanfacin Guanfacine - Affective Dysregulation | Unknown | Technische Universität Dresden | 40 | 2020-04-01 | 2020-04-06 | |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: - Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension | Recruiting | Duke University | 5000 | 2020-03-05 | 2026-08-21 | |
| Percutaneous Ultrasonic Tenotomy Versus Platelet Rich Plasma for Gluteal Tendinopathy Leukocyte-Rich Platelet-Rich Plasma, Percutaneous Ultrasonic Tenotomy - Gluteal Tendinitis, Trochanteric Bursitis | Not applicable | Withdrawn | Andrews Research & Education Foundation | 2020-02-20 | 2022-08-11 | |
| ACEI or ARB and COVID-19 Severity and Mortality in US Veterans ACEI/ARB, Non-ACEI/ARB, ACEI - Hypertension, COVID | Completed | University of Utah | 22213 | 2020-01-19 | 2021-04-28 | |
| Efficacy of Guanfacine and Lidocaine Combination in Trigeminal Nerve Block for Pain Management in Trigeminal Neuropathy Lidocaine, Guanfacine - Trigeminal Neuralgia | Phase 2 | Completed | Vanderbilt University Medical Center | 37 | 2019-11-04 | 2025-03-30 |
| Guanfacine to Improve Substance Use Outcomes in Women Guanfacine, Behavioral Counseling - Substance Use Disorders | Phase 2 | Completed | Yale University | 74 | 2019-11-01 | 2024-03-20 |
| A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan MPH (Concerta), MPH (Ritalin), Atomoxetine (ATO) - Attention Deficit Disorder With Hyperactivity | Completed | Janssen Research & Development, LLC | 17418 | 2019-10-01 | 2025-04-27 | |
| A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD) Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo - Attention Deficit Hyperactivity Disorder | Phase 4 | Completed | Shire | 396 | 2019-09-18 | 2026-04-13 |
Showing 20 of 76. Sign in to see all of them.
Attention Deficit Disorder with Hyperactivity (29) · Hypertension (5) · Cognitive Dysfunction (4) · Aggression (3) · Impulsive Behavior (3) · Pain (3) · Spasm (3) · Agnosia (2) · Alcohol Drinking (2) · Alcoholism (2) · Autistic Disorder (2) · Child Development Disorders, Pervasive (2) · Chronic Pain (2) · Critical Illness (2) · Delirium (2)
Shire (15) · Yale University (12) · Icahn School of Medicine at Mount Sinai (3) · Massachusetts General Hospital (3) · New York State Psychiatric Institute (3) · Vanderbilt University Medical Center (3) · Gilead Sciences (2) · Imperial College London (2) · Stanford University (2) · Andrews Research & Education Foundation (1) · Children's Hospital Medical Center, Cincinnati (1) · Children's Specialized Hospital (1) · Duke University (1) · Indiana University (1) · Janssen Research & Development, LLC (1)
United States (61) · United Kingdom (6) · Canada (4) · Germany (4) · Spain (4) · Sweden (4) · Australia (3) · Austria (3) · Belgium (3) · France (3) · Argentina (2) · Brazil (2) · Ireland (2) · Italy (2) · Netherlands (2)
Sherry A McKee, PhD (4) · Helen C Fox, PhD (2) · Jianren Mao, M.D., Ph.D. (2) · Rajita Sinha, PhD (2) · Sherry McKee, PhD (2) · Adam P Bress, PharmD, MS (1) · Andrew Barker, MD (1) · Antonia S. New, M.D. (1) · Asima F Zehgeer, MD (1) · Barbara J Coffey, MD, MS (1) · Bryan King, MD (1) · Carolyn A Denton, Ph.D. (1) · Chi Hornik (1) · Christopher H van Dyck, MD (1)
PMID 37029295, PMID 37811711, PMID 10851208, PMID 11927799, PMID 12119802, PMID 12923400, PMID 15738343, PMID 16275814, PMID 16391172, PMID 16533484, PMID 16950221, PMID 17448997, PMID 18166547, PMID 18426998, PMID 19047577, PMID 19106767, PMID 19519256, PMID 19738158, PMID 19877974, PMID 20806988, PMID 20921430, PMID 21476931, PMID 22176941, PMID 22801444, PMID 23266540, PMID 23519656, PMID 23615868, PMID 23972694, PMID 24395021, PMID 25109412, PMID 25245353, PMID 25306494, PMID 25453486, PMID 26506582, PMID 26547425, PMID 26730446, PMID 27268111, PMID 27453079, PMID 27453080, PMID 27453081, PMID 27483130, PMID 27663654, PMID 27788903, PMID 27868077, PMID 28165762, PMID 28823835, PMID 29293361, PMID 29436486, PMID 29442229, PMID 30031963
P01AA027473 (2), P50DA033945 (2), R01DA035001 (2), R01DA036564 (2), U54AA027989 (2), 2008 (1), 2018 (1), P50MH077248 (1), R01AA022285 (1), R01AA031662 (1), R01AG053582 (1), R01DA021690 (1), R01DA027130 (1), R01DA047094 (1), R01DA047986 (1)